Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced business highlights and consolidated results for the third quarter and nine months ended September 30, 2012.
Financial Results and Outlook
For the quarter ended September 30, 2012, Navidea reported a net loss attributable to common stockholders of $9.1 million, or $0.09 per share, compared to net income attributable to common stockholders of $19.8 million, or $0.21 per share, for the same period in 2011. For the nine months ended September 30, 2012, Navidea’s net loss attributable to common stockholders was $22.0 million, or $0.23 per share, compared to net income attributable to common stockholders of $13.1 million, or $0.15 per share, for the same period in 2011. In August 2011, the Company sold its neoprobe ® GDS line of gamma detection device systems to a third party. As a result, the Company recorded a net pre-tax gain on the sale of the GDS business of approximately $25 million during the third quarter of 2011.
Research and development (R&D) expenses were $6.1 million for the quarter ended September 30, 2012, compared to $3.9 million for the same period in 2011. The increase in R&D expenses was attributable to several factors, including increases in NAV4694 (previously called AZD4694) and NAV5001 (previously called CFT) development activities including $1.3 million in NAV5001 sublicense fees, Lymphoseek ® manufacturing-related costs, and headcount-related costs to support our growing development activities, offset by reductions in Lymphoseek new drug application (NDA) filing fees, Lymphoseek clinical trial activities, and RIGScan™ development costs.R&D expenses were $12.5 million for the nine months ended September 30, 2012, compared to $8.2 million for the same period in 2011. The increase in R&D expenses was primarily attributable to the same factors described above for the three-month periods as well as an option fee and diligence-related costs associated with our sublicense of NAV5001.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV